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Abstract
Due to remarkable improvements in heart failure (HF) management over the last 30 years, a significant reduction in mortality 
and hospitalization rates in HF patients with reduced ejection fraction (HFrEF) has been observed. Currently, the optimiza-
tion of guideline-directed chronic HF therapy remains the mainstay to further improve outcomes for patients with HFrEF 
to reduce mortality and HF hospitalization. This includes established device therapies, such as implantable defibrillators 
and cardiac resynchronization therapies, which improved patients’ symptoms and prognosis. Over the last 10 years, new HF 
drugs have merged targeting various pathways, such as those that simultaneously suppress the renin–angiotensin–aldosterone 
system and the breakdown of endogenous natriuretic peptides (e.g., sacubitril/valsartan), and those that inhibit the If channel 
and, thus, reduce heart rate (e.g., ivabradine). Furthermore, the treatment of patient comorbidities (e.g., iron deficiency) has 
shown to improve functional capacity and to reduce hospitalization rates, when added to standard therapy. More recently, 
other potential treatment mechanisms have been explored, such as the sodium/glucose co-transporter inhibitors, the gua-
nylate cyclase stimulators and the cardiac myosin activators. In this review, we summarize the novel developments in HFrEF 
pharmacological and device therapy and discuss their implementation strategies into practice to further improve outcomes.
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Novel heart failure treatments
Sodium/glucose cotransporter 2 inhibitors
Sodium/glucose cotransporter 2 (SGLT2) inhibitors reduce 
cardiovascular (CV) mortality and heart failure (HF) hospi-
talizations in patients with diabetes mellitus (DM) in stud-
ies were signs and symptoms of HF were not required for 
inclusion [1, 2]. These findings led to the hypothesis that 
SGLT2 inhibitors may represent an effective treatment of 
HF independent of the DM status [3]. Accordingly, pro-
spective, controlled trials were designed to investigate the 
effect of SGLT2 inhibitors, dapagliflozin (DAPA-HF, 3) and 
empagliflozin (EMPEROR-Reduced, 4) in HF with reduced 
ejection fraction (HFrEF) patients. Dapagliflozin resulted 
in a 26% reduction in the primary endpoint of CV death, 
HF hospitalizations and urgent presentations for worsening 
HF [3]. This resulted in a "number needed to treat" (NNT) 
of 21 patients, i.e., 21 patients need to be treated to prevent 
one of these events. In the DAPA-HF trial, all components 
of the primary endpoint were similarly reduced and there 
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was no heterogeneity between subgroups [3]. The treatment 
effects of dapagliflozin were not different across all groups 
of renal function at baseline [5]. Recently, the EMPEROR-
Reduced trial showed a consistent 25% reduction in the pri-
mary endpoint of CV death and HF hospitalizations when 
empagliflozin was added to established therapy in symp-
tomatic patients with HFrEF [4]. In EMPEROR-Reduced, 
there was a 30% reduction in all HF hospitalizations (the first 
and all subsequent) and a significant reduction in worsening 
of renal function over time, reflecting a nephro-protective 
effect. Similarly, endpoints consisting of dialysis require-
ment, decline in estimated glomerular filtration rate (eGFR) 
by >  = 40% or death from renal or CV disease were reduced 
by 50% [4, 6]. Since phase II trials have shown that a natriu-
retic and glucosuric effect occurs not only in DM but also in 
non-DM patients, DAPA-HF and EMPEROR-Reduced were 
conducted in patients with and without DM [3–6]. Two large 
analyses showed that effects on endpoints for both drugs [7, 
8] were not different in patients with or without DM. There 
was also no difference in the treatment effect of empagliflo-
zin or dapagliflozin across the spectrum of HbA1C levels 
[7, 8]. Additionally, the marked reduction of CV death and 
HF hospitalizations and the renal end point (slope of the 
change in eGFR) was similar in patients with and without 
ARNI treatment at baseline [9]. Furthermore, in HF, low 
blood pressure is a problem that often discourages physi-
cians from prescribing guideline-guided therapies. This is 
related to a fear of adverse drug effects as most of effective 
HF agents and to the fact that low blood pressure associates 
with poor prognosis [10–12]. Since SGLT2 inhibitors also 
lower blood pressure in hypertensive patients [13], there was 
concern that SGLT2 inhibitors also lower blood pressure 
in HF to a range that leads to intolerance [14]. However, 
DAPA-HF trial showed only a small drop (1–2 mmHg) in 
blood pressure, which was negligible in patients with low 
baseline blood pressure (< 110 mmHg). At follow-up, blood 
pressure values rose again [15]. Correspondingly, there were 
no significant differences in side effects in the individual 
blood pressure groups and no increased discontinuation 
rates due to low blood pressure [15]. Taking together, this 
therapy appears to be cost-effective [16], and so far, no sub-
group showed more or less therapeutic effects in both tri-
als. For the SGLT1/2 inhibitor, sotagliflozin, the SCORED 
trial including patients with DM with and without HF [17] 
and SOLOIST (HF trial with inclusion of patients immedi-
ately after decompensation in patients with DM) [18] were 
conducted. The endpoint of reduction of CV death and HF 
hospitalizations was also shown. These trials were stopped 
early due to the COVID-19 pandemic and loss of sponsor-
ing and recruited less than half of the planned number of 
patients. Nevertheless, the results were striking enough to 
confirm the data from the DAPA-HF [3] and EMPEROR-
Reduced trials [4].
Vericiguat (guanylate cyclase activator)
In CHF, the impaired formation of cyclic guanosine 
monophosphate (cGMP), contributes to endothelial dys-
function and possibly causes myocardial relaxation impair-
ment [19]. Vericiguat is an orally available guanylate 
cyclase stimulator that activates the formation of cGMP 
via direct stimulation of guanylate cyclase [19]. As such, 
it directly stimulates the formation of nitric oxide (NO), 
but also increases the sensitivity to endogenous NO [19]. 
Preliminary studies have shown that vericiguat is safe and 
leads to a decrease in N-terminal pro B-type natriuretic 
peptide (NT-proBNP) concentrations [20]. In light of these 
encouraging results, the VICTORIA trial was designed 
to include patients with more severe HF, some of whom 
were randomized immediately after acute decompensa-
tion [21]. The VICTORIA trial showed a significant 10% 
reduction in the combined endpoint of CV death and HF 
hospitalizations, although the individual endpoint compo-
nents were not significantly reduced [21]. However, given 
the high incidence of events in the placebo arm, which was 
up to 50% over 20 months, the absolute risk reduction was 
about 4%, which is in line with the absolute risk reduction 
observed in other trials. Whilst the discussion about the 
position of vericiguat amongst HFrEF therapy is ongoing, 
it is possible that this novel drug may have a role in the 
treatment of severe HFrEF patients in the aftermath of a 
recent hospitalization added to other established HFrEF 
therapies. Vericiguat has been approved by the Food and 
Drug Administration (FDA), while approval by European 
Medicines Agency (EMA) is pending.
Omecamtiv mecarbil (myosin activator)
Omecamtiv mecarbil activates the interaction of myosin 
with actin, leading to an increase in contractility force and 
contraction duration [22]. Shortening of systolic ejection 
time is a described phenomenon in HF [23] and led to the 
speculation that beneficial effects in HF may be achieved 
via directly modulating ejection time. The Chronic Oral 
Study of Myosin Activation to Increase Contractility in 
Heart Failure (COSMIC-HF) [23] was a phase II trial that 
showed a decrease in NT-pro-BNP levels, heart rate and 
in ventricular dimensions [23]. More recently, the Car-
diac Myosin Activation with Omecamtiv Mecarbil in Sys-
tolic Heart Failure (GALACTIC-HF) trial studied 8256 
patients in a randomized fashion to omecamtiv mecarbil 
or placebo [24]. There was a nominal (8%) reduction in 
the composite endpoint of CV death and HF hospitaliza-
tion, and this effect was formally significant (p = 0.03). 
The components of the primary endpoint, however, and 
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the all-cause mortality were not significantly reduced. 
GALACTIC-HF showed that this medication is safe, and 
despite the inclusion of patients with baseline blood pres-
sure of 80 mmHg, there was no drop in blood pressure 
with omecamtiv mecarbil. Furthermore, GALACTIC-HF 
included patients who were acutely decompensated, with 
30% of patients randomized while still in hospital [25]. 
Unpublished subgroup analyses indicate that patients in 
sinus rhythm with low (ejection fraction) EF below the 
median of 28% and with particularly elevated NT-pro-BNP 
may benefit from this therapy [25]. Although the study 
is formally positive, an approval by drug authorities and 
further clinical development is unknown at this time.
Intravenous iron therapy
Iron deficiency is present in approximately 50% of patients 
with HF and is associated with reduced exercise capacity 
and quality of life independently of anemia [26–28]. Previ-
ous studies showed beneficial effects of intravenous iron in 
the preparation form of intravenous ferri-carboxymaltose on 
exercise capacity and quality of life and in non-statistically 
preplanned analyses with trends of reduction in hospitaliza-
tion and death [28]. The recently published AFFIRM-AHF 
study showed that among patients with acute HF and iron 
deficiency, intravenous ferric carboxymaltose was associated 
with a numerical reduction in total HF hospitalizations and 
CV death. The trial narrowly missed its primary endpoint 
of total hospitalizations and CV death but did demonstrate a 
significant 26% drop in total HF hospitalizations [29]. Inter-
estingly, recruitment was also affected by the COVID-19 
pandemic. The study was stopped in the countries as soon 
as the first COVID-19 case occurred there. Nevertheless, 
the authors conclude that with the concerted approach to the 
COVID-19 epidemic by the European Society of Cardiol-
ogy (ESC) [30], the results show a reliable decrease in the 
hospitalization rate.
Sudden cardiac death in HF patients: risk 
stratification and device therapy
Implantable cardioverter-defibrillator (ICD) Implantation 
is the main therapy for prevention of sudden cardiac death 
(SCD) in many patients with HF and left ventricular ejec-
tion fraction (LVEF) < 35% [31, 32]. In patients with HFrEF, 
improvements in pharmacological therapies might lead to an 
improvement in LVEF and consequently, some patients lose 
their ICD indication for primary prevention of SCD.
Moreover, the DANISH trial showed that ICD for primary 
prevention did not show significant beneficial effects on CV 
and all-cause death in very well-treated, including cardiac 
resynchronization (CRT), patients with non-ischemic dilated 
cardiomyopathy [31], whereas only the incidence of SCD 
was significantly reduced (p = 0.005). However, an explora-
tory subgroup analysis showed a significant survival benefit 
for patients ≤ 70 years (p = 0.03). Interestingly, a recently 
published multicenter European study emphasizes the 
importance of scarring for assessing the risk of SCD beside 
LVEF in HF patients [33]. Patients with a CRT indication 
were prospectively included in this observational study. Car-
diac magnetic resonance imaging (CMR) was performed in 
all patients. The primary endpoint was a composite of sus-
tained ventricular tachycardia (VT) / ventricular fibrillation 
(VF), adequate ICD therapy, or SCD. A total of 218 patients 
with LVEF of 26 ± 7% were analyzed with a median follow-
up of 45 months. A myocardial scar was detected in 95% in 
patients with ischemic cardiomyopathy and 45% in patients 
with non-ischemic cardiomyopathy. Scar was detectable in 
83% of patients who met the primary endpoint. Additionally, 
the scar detectable on MRI was the only significant predic-
tor for the primary endpoint regardless of LVEF response to 
CRT (odds ratio, 27.7; 95% CI 3.8–202.7). Consistent with 
previous reports, this study underlines the importance of a 
myocardial scar in the occurrence of VT/VF in patients with 
reduced LVEF [33]. Therefore, scar assessment should be 
considered as an important parameter for SCD risk stratifica-
tion in addition to LVEF.
Furthermore, it is still currently unclear which patients 
with a CRT indication actually benefit from a defibrilla-
tor in addition to the pacemaker. A recent study analyzed 
45,679 patients treated with a CRT-P or CRT-D system for 
primary prevention in France between 2010 and 2017 [34]. 
During a follow-up of 913 days, the incidence of mortality 
was higher in CRT-P (12%) than in CRT-D patients (7%). 
Nonetheless, there was no significant mortality difference 
between CRT-P and CRT-D in patients older than 75 years 
with non-ischemic cardiomyopathy. In contrast, CRT-P 
patients younger than 75 years with non-ischemic cardio-
myopathy showed higher mortality than CRT-D patients 
(p = 0.02). Interestingly, mortality was higher in CRT-P 
versus CRT-D patients with ischemic cardiomyopathy in 
all groups of patients. Until randomized data are available, 
this study might add a support value in selection of CRT-
system. Moreover, this study illustrates that CRT-D therapy 
was associated with a significant lower all-cause mortality 
regardless of etiology and patient age [34].
Atrial fibrillation and HF
Atrial fibrillation (AF) is a common and prognostically unfa-
vorable comorbidity in patients with HF [35, 36]. Although 
restoration and maintenance of sinus rhythm would be ideal 
for these patients, several studies comparing rhythm and rate 
control have failed to show any advantage of rhythm control 
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achieved with pharmacological therapy in terms of HF hospi-
talization or death [37, 38]. Catheter ablation is an established 
therapy for symptomatic AF patients who do not respond to 
medical therapy and have normal cardiac function [38, 39]. 
Furthermore, early rhythm-control therapy has been associ-
ated with a lower risk of adverse CV outcomes than usual care 
among patients with a history of CV disease within the first 
year of AF diagnosis [40]. Several recent studies have shown 
improvement in clinical outcomes after AF ablation in HF 
patients, highlighting the growing importance of the invasive 
approach in this patient population [39]. The recent Catheter 
Ablation vs. Standard Conventional Therapy in Patients with 
Left Ventricular Dysfunction (CASTLE-AF) trial was the first 
randomized trial investigating the impact of AF catheter abla-
tion compared with medical therapy (rate or rhythm control) 
on mortality and hospitalizations in patients with HF. Symp-
tomatic AF patients with (LVEF < 35%) participated in the 
study. A significant reduction in the composite endpoint of 
death and HF hospitalization was shown in the catheter abla-
tion group compared with the medical therapy one [39]. More 
recently, the Catheter Ablation vs. Medical Rate Control in 
Atrial Fibrillation and Systolic Dysfunction (CAMERA-MRI) 
trial randomized patients with idiopathic cardiomyopathy and 
persistent AF who underwent CMR to either catheter ablation 
or rate control therapy [39]. There was a significant improve-
ment in LVEF in patients who underwent catheter ablation 
compared with those who were randomized to drug therapy 
despite optimal rate control. Patients with no evidence of late 
gadolinium enhancement (LGE) on CMR had better improve-
ments in their LV function after the ablation compared with 
those who had LGE. This result showed that CMR might be 
a strong tool to identify HF patients who may benefit more 
from catheter ablation [39]. However, the AMICA trial (Atrial 
Fibrillation Management in Congestive Heart Failure With 
Ablation) did not reveal any benefit of catheter ablation in 
patients with persistent AF and EF < 35. One year after abla-
tion, LVEF displayed a comparable increase as in patients on 
best medical therapy without ablation [41]. Current guidelines 
recommend catheter ablation of AF to resolve LV dysfunction 
in AF patients when tachycardia-induced cardiomyopathy is 
highly likely, regardless of their symptom status (Class I rec-
ommendation) [38]. In conclusion, catheter ablation appears 
promising in patients with AF and HF. Some concerns remain 
regarding patient selection and standardization of the ablation 
procedure to best balance the risks and benefits of the proce-
dure in this population.
Has the maximum benefit been reached?
Patients with HF have a substantially shorter life expec-
tancy than age-adjusted groups of patients without HF 
[42]. Intensive anti-neuroendocrine therapy has generally 
been successfully delivered in a stepwise fashion with the 
addition of the next agent in the recent years, which is the 
basis for the stepwise guideline recommendations [42]. An 
open question is whether intensive therapy with newer sub-
stances, such as SGLT2 inhibitors and angiotensin receptor/
neprilysin inhibitors (ARNI), lead to a further reduction in 
HF outcomes or whether the beneficial effects have maxi-
mally reached and thus no further effect can be achieved by 
polypharmacotherapy. In a "meta-network analysis", which 
implies the comparison of all placebo-controlled trials with 
pooled placebo groups, the efficacy of individual substances 
was investigated [43]. This showed a 42% decrease in all-
cause mortality with a fully complete combination of four 
HF agents [angiotensin-converting enzyme (ACE) inhibi-
tors, beta-blocker, mineralocorticoid antagonist (MRA) 
with ivabradine] and 52% with ARNI added to beta-blocker 
and MRA therapy [43]. Furthermore, it has been shown 
that additional therapy adding an SGLT2 inhibitor and an 
ARNI leads to an extra benefit and increased life expectancy 
compared with conventional therapy with an ACE inhibitor, 
angiotensin receptor blocker (ARB) or beta-blocker, which 
is dependent on the patient’s age at diagnosis of HF [44]. 
For example, it has been shown that when therapy is started 
at age 55, the increase in life expectancy is about 6–7 years 
[43, 44]. This clearly demonstrates that the use of different 
drugs mechanisms: anti-neuroendocrine therapy with beta-
blockers and ACE inhibitors/ ARB, support of adaptive 
mechanisms with neprilysin inhibition or metabolic effects 
with SGLT2 inhibitors (partly unexplained) have achieved 
further additive benefits in addition to previous therapies 
[44]. Accordingly, drug “poly-pharmacotherapy” in CHF 
appears to be justified.
Should we move to individualized 
rather than chronological treatment 
recommendation?
Previous guideline recommendations were based on the 
time when the evidence for effective therapies was gener-
ated. For example, in early trials of ACE inhibitors, such as 
CONSENSUS-I, therapy was compared only with diuretics 
and occasionally digitalis therapy [45]. In this respect, in 
the previous HF guidelines ACE inhibitor was always in 
the first place. Recently, the CIBIS III study [46] showed 
a similar morbidity and mortality statistics with concomi-
tant initiation of enalapril or bisoprolol. Therefore, current 
guidelines recommend beta-blockers and ACE inhibitors as 
an initial therapy [42]. The initiation of therapy in stable 
patients, long after decompensation, often leads to delayed 
start of drug therapy and patients are not well treated espe-
cially after discharge, where a particularly high mortality 
and hospitalization rate occurs [47, 48]. This due to the 
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evidence from the most controlled clinical trials, which 
was generated only after discharge in stable ambulatory 
patients long time after their hospitalization with worsen-
ing HF (Fig. 1). Due to registries showing benefits, when 
treatment is started immediately after decompensation and 
even before discharge, an early initiation of therapy could 
be recommended. Most importantly, novel treatments with 
SGLT2 inhibitors and ARNI, even at low starting doses, 
resulted in a statistically significant end-point reduction 
within the first 30 days after randomization [49, 50]. This 
highlights that subsequently therapy with all four founda-
tional HFrEF drugs, namely ARNI, beta-blockers, MRA, 
and SGLT2 inhibitors, should therefore be achieved within 
4 weeks in HFrEF patients [51, 52]. Other HF medications 
should also be implemented promptly according to patient 
characteristics to improve outcomes [51, 52]. This approach 
was already implemented in the new Canadian Cardiovas-
cular Society HF guidelines update, which strongly recom-
mended that HFrEF patients should be initially treated with 
combination therapy from each of the following categories 
(ARNI/ACEI, B-blocker, MRA and SGLT2 inhibitor) [53]. 
Other therapies should be individualized to subgroups based 
on clinical scenario (ICD/CRT, ivabradine in sinus rhythm 
above 70 beats/min, assist systems, heart transplantation, 
etc.). New substances, such as vericiguat and omecamtiv 
mecarbil, have achieved statistically significant effects but 
with a limited effect size in reducing the primary endpoint 
but neutral results in key secondary outcomes, such as CV 
and all-cause death. Presently, it is open whether omecamtiv 
will get a market approved therapeutic agent. It would be 
conceivable that vericiguat and potentially also omecamtiv 
could be recommended for patients with advanced HFrEF 
after a recent hospitalization for worsening of heart failure. 
A summary of all possible interventions including those for 
subgroups and those for special situations is shown in Fig. 2.
Heart failure is an urgency needing rapid 
intervention
Despite remarkable improvements in HF care, it is still 
a globally progressive condition with more than 37 mil-
lion patients worldwide [42, 54]. According to the clinical 
presentation, the HF syndrome can be classified into acute 
or chronic [54], and further into acute HF (AHF) defined 
as new (de novo) HF or worsening of symptoms and signs 
of pre-existing chronic HF (CHF) [42]. Worsening of 
CHF accounts for 80–90% of those patients hospitalized 
while only 10–20% have new-onset or advanced HF [54, 
55]. Currently, hospitalization due to AHF is still asso-
ciated with poor outcomes, with re-hospitalization rates 
and 1-year mortality up to 30% [54–56]. Accordingly, the 
importance of early diagnosis and rapid intervention has 
been highlighted in the recent HF guidelines; however, 
Fig. 1  A schematic scheme of 
the association of outcomes, 
treatment initiation, missed 
opportunities and potential 
benefits of early intervention in 
HF patients. The Figure shows 
landmark HF trials during the 
period where patients were 
included in those studies. Data 
taken from [3, 4, 18, 21, 25, 
57, 61]
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timelines were not stated [42, 57]. A recent multinational 
registry showed that regardless of admission via the emer-
gency department, normal ward or the intensive care unit 
in Western Europe, the median time to initiation of a diu-
retic was around 3 h [56]. “Door to Diuretic” (D2D) time 
was significantly longer in North America compared with 
other regions like Eastern Europe and Southeast Asia [56]. 
A Japanese registry showed that rapid volume unloading 
within the first 30 min is associated with improved progno-
sis than delaying the first relieving diuretic therapy beyond 
one hour [58]. The authors recommend that it is useful to 
work with strict timelines in acute decompensation and to 
complete patient evaluation and diagnostics within 5 min, 
and subsequently to start decongestion therapy within the 
first 20 min [58]. These data strongly support the pre-
viously mentioned recommendation of rapid initiation 
of therapy in patients with AHF, which can essentially 
be achieved by rapid diuretic therapy [57, 59]. An early 
decrease of wall tension, and consequently neuroendocrine 
activation, with a potential reduction of myocyte damage 
could provide long term benefit [59, 60], in addition to 
the fact that rapid relief of symptoms of congestion is an 
ethical requirement. Therefore, the concept of "time is 
muscle" also seems to be of importance in AHF, as is 
well established in acute coronary syndromes (58). Conse-
quently, there is a clinical challenge and an urgent need for 
Fig. 2   Overview on management of heart failure with reduced ejec-
tion fraction (HFrEF). ARNI/ACEi/ARBs, B-blockers, MRA, and 
SGLT2 inhibitors are indicated as soon as possible for all HFrEF 
patients (4 pillars of optimal HFrEF medical therapy). This is followed 
by devices or other drug therapies. Subgroups with: SR and HF > 70, 
LBBB with QRS > 130  ms, recurrent decompensation/advanced HF, 
self-identified blacks will treat accordingly. Comorbidities such as 
iron deficiency, MR, AF will treat appropriately. Diuretic is given 
for severe congestion across the whole spectrum. An ICD should be 
implanted due to the risk of malignant arrhythmias if left ventricular 
function is consistently reduced (LVEF < 35%) ACE-I: angiotensin-
converting enzyme inhibitor, AF: atrial fibrillation, ARNI: angioten-
sin receptor/neprilysin inhibitor, BAT: Baroreflex activation therapy, 
B-blocker: beta-blocker, CCM: Cardiac contractility modulation, CRT : 
cardiac resynchronization therapy, HF: heart failure, HTX: heart trans-
plantation, Hy: hydralazine, ICD: implantable cardiac defibrillator, 
ISDN: Isosorbide dinitrate, LBBB: left bundle branch block, LVAD: 
left ventricular assist device, LVEF: left ventricular ejection fraction, 
MR: mitral regurgitation, MRA: mineralocorticoid receptor antagonist, 
MVR: mitral valve repair, PVI: pulmonary vein isolation, QoL: qual-
ity of life, SGLT2: sodium–glucose co-transporter 2, SR: sinus rhythm, 
TSAT: transferrin saturation
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early identification of HF patients and rapid interventions 
to interrupt the progression of this disease.
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